
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc. is poised for significant financial growth, with expectations for mid-teens revenue growth and potential acceleration into the high-teens by 2026, driven by new product launches and reduced regulatory headwinds, particularly in the neurovascular segment. The company's ability to increase gross and operating margins alongside projected EPS growth that outpaces revenue growth further enhances its financial outlook. Additionally, Penumbra's position as a market leader with robust innovation in the thrombectomy space positions it favorably for continued market penetration and share capture from competitors, reinforcing its attractiveness as an investment opportunity.
Bears say
Penumbra Inc faces significant risks that may hinder its future growth, such as increased competition in the mechanical thrombectomy market and potential delays in new product approvals. Additionally, challenges related to reimbursement changes could place pressure on the company's revenue stream and limit physician interest in its devices. Furthermore, if clinical trial outcomes do not demonstrate a clear advantage for Penumbra's technologies compared to existing alternatives, the company's ability to capture market share and grow its business may be severely constrained.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares